

SUPPLEMENTAL MATERIAL

Schatz et al., <http://www.jem.org/cgi/content/full/jem.20110846/DC1>**Table S1.** Complete PIM1 and PIM2 lymphoma TMA scoring results

Disease	Cases	0	1	2	% pos.	Cases	0	1	2	% pos.	% neg.	% pos.
DLBCL	166	86	68	12	48.2	163	94	50	19	42.3	32	25
CLL/SLL	33	8	14	11	75.7	33	25	7	1	24.2	24	24
FL	200	117	58	25	42.5	203	142	51	10	30.0	37	8
MCL	30	4	17	9	86.7	33	25	8	0	24.2	10	21

Table S2. Follicular lymphoma patients' clinical characteristics (*n* = 66)

Characteristics	PIM		P-value
	Positive (<i>n</i> = 43)	Negative (<i>n</i> = 23)	
Age at diagnosis, yr/mean ± SD/median (range)	60.9 ± 12.2 61.3 (33.9–80.8)	52.6 ± 11.5 52.6 (31.1–69.9)	0.009
Sex, n (%)			
Male	20 (47)	11 (48)	0.92
Female	23 (53)	12 (52)	
Doxorubicin-based therapy, n (%)			
No	19 (44)	6 (26)	0.11
Yes	22 (51)	17 (74)	
NA	2 (5)	0 (0)	

NA, not available; these two patients were excluded from analysis.

Table S3. DLBCL patients' clinical characteristics (*n* = 116)

Characteristics	PIM		P-value
	Positive (<i>n</i> = 72)	Negative (<i>n</i> = 44)	
Age at diagnosis, years/median (min, max)	60.3 (10.0-82.0)	55.9 (29.0-89.6)	0.28
Sex, n (%)			
Male	34 (47)	16 (36)	0.25
Female	38 (53)	28 (64)	
Stage, n (%)			
I	7 (10)	4 (9)	0.85
II	7 (10)	2 (5)	
III	3 (4)	1 (2)	
IV	9 (13)	5 (11)	
Unknown	46 (64)	32 (73)	
IPI risk factors, n (%)			
0	3 (4)	0 (0)	0.15 ¹
1	2 (3)	6 (14)	
2	7 (10)	4 (9)	
3	5 (7)	6 (14)	
4	5 (7)	3 (7)	
5	1 (1)	0 (0)	
Unknown	49 (68)	25 (57)	
Doxo-based therapy, n (%)			
No	13 (18)	1 (2)	0.01
Yes	59 (82)	43 (98)	
RT, n (%)			
No	54 (75)	34 (77)	0.78
Yes	18 (25)	10 (23)	

¹ Analysis was based on risk factor 0, 1, 2, 3, and 4/5.

Table S4. Statistical analyses of follicular lymphoma patients (*n* = 66)

Comparison	+ Median TTE (Mo)	- Median TTE (Mo)	Log-Rank <i>P</i>	HR (CI)	+ Median OS (Mo)	- Median OS (Mo)	Log-Rank <i>P</i>	HR (CI)
Combined	27.24	51.63	0.0113	0.4754 (0.2675-0.8448)	104.9	222	0.0372	0.4992 (0.2597-0.9597)
Pim1	33.43	24.21	0.328	0.7529 (0.4264-1.330)	104.9	136.3	0.1964	0.6516 (0.3403-1.248)
Pim2	24.18	38.77	0.1507	0.6301 (0.3356-1.183)	116.6	175.2	0.2551	0.6694 (0.3354-1.336)
DP	55.13	27.24	0.8325	1.083 (0.5155-2.277)	128.8	116.6	0.7257	0.8564 (0.3601-2.037)

Comparisons - Combined: Positive for any Pim (+) versus double negative (-); Pim1 positive versus negative; Pim2 positive versus negative; DP: Both Pim1 and Pim2 positive (+) versus others (-). TTE: Time to event (death, progression of disease, or secondary malignancy) since initiation of initial therapy. OS, overall survival, HR, Hazard ratio; CI, 95% confidence interval

Table S5. Statistical analyses of DLBCL patients (*n* = 116)

Comparison	+ Median TTE (Mo)	- Median TTE (Mo)	Log-Rank <i>P</i>	HR (CI)	+ Median OS (Mo)	- Median OS (Mo)	Log-Rank <i>P</i>	HR (CI)
Combined	67.42	167.1	0.4461	0.7876 (0.4261-1.456)	126.3	Undefined	0.1678	0.5905 (0.2794-1.248)
Pim1	67.42	97.45	0.5688	0.8383 (0.4571-1.537)	83.68	Undefined	0.1837	0.6012 (0.2839-1.273)
Pim2	59.83	104.8	0.4933	0.8071 (0.4372-1.490)	Undefined	Undefined	0.9771	0.9889 (0.4629-2.113)
DP	59.1	97.45	0.5548	0.8042 (0.3902 to 1.657)	83.68	Undefined	0.9765	1.014 (0.4112-2.499)

Comparisons - Combined: Positive for any Pim (+) vs double negative (-); Pim1 positive vs negative; Pim2 positive vs negative; DP: Both Pim1 and Pim2 positive (+) vs others (-). TTE: Time to event (death, progression of disease, or secondary malignancy) since initiation of initial therapy; OS: Overall survival, HR: Hazard ratio; CI: 95% confidence interval